Neurology

The experimental treatment AMX003 prolonged survival in patients with amyotrophic lateral sclerosis (ALS), according to results from the CENTAUR trial.

In the trial, patients with ALS were randomized 2:1 to receive AMX003, which is combination of sodium phenylbutyrate and taurursodiol, or placebo. Patients who completed a 24-week randomized phase were eligible to receive AMX003 in the open‐label extension. At 35‐month maximum follow‐up post‐randomization, an all‐cause mortality analysis…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Journal Scan

  1. Oct 19, 2020

Investigational treatment prolongs survival in ALS

The experimental treatment AMX003 prolonged survival in patients with amyotrophic lateral sclerosis (ALS), according to results from the CENTAUR trial.

In the trial, patients with ALS were randomized 2:1 to receive AMX003, which is combination of…